Loading…
Employees: 5,716
Size Jinling Pharmaceutical (000919.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $586M, the 3477th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.36 on 6 Nov 2026.
Performance Over six months the shares fell 13.9%, against -21.4% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 7.8% over the last twelve months (peer median +4.5%); the operating margin is 0.6% (peer median 4.5%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 5.4× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.17B | CN¥3.19B | CN¥3.28B | CN¥3.19B | CN¥2.66B |
| Revenue growth | — | -3% | +3% | +20% | — |
| Gross profit | CN¥754M | CN¥600M | CN¥541M | CN¥580M | CN¥483M |
| EBITDA | n/a | CN¥106M | CN¥198M | CN¥233M | CN¥179M |
| Net income | CN¥44.4M | CN¥53.9M | CN¥40.4M | CN¥106M | CN¥105M |
| Free cash flow | CN¥181M | CN¥53.5M | -CN¥10.5M | CN¥14.9M | -CN¥23.7M |
| Capital expenditure | CN¥167M | CN¥158M | CN¥202M | CN¥238M | CN¥310M |
| Total debt | CN¥192M | CN¥234M | CN¥233M | CN¥114M | CN¥104M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000919.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.1% | -8.2% | 6th highest of 21 |
| 6-month return | -13.9% | -21.4% | 9th highest of 21 |
| Distance from 52-week high | -35.1% | -35.8% | 9th highest of 21 |
| Revenue growth (TTM) | -7.8% | +4.5% | 7th lowest of 20 |
| Operating margin | 0.6% | 4.5% | 9th lowest of 19 |
| EV / Sales | 0.8× | 5.4× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 1.1% | 5th least demanding of 9 |
| Growth delivered (Del g) | +5.0% | +8.2% | 4th lowest of 9 |
| Hurdle (Req g minus delivered) | +0.0 pp | -6.7 pp | 4th most demanding of 9 |
| ROIC minus cost of capital | -3.4 pp | -1.5 pp | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |